Therefore, FRMD3 would act as a tumor suppressor in breast cancer, and its downregulation would be associated with poor clinical outcomes in breast cancer patients, indicating its potential as a prognostic marker and therapeutic target for breast cancer metastasis prevention and therapy. The gene discussed is FRMD3; the disease is breast carcinoma.